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1. Introduction 
Prostate cancer (PCa) is the most common male non-dermatological cancer in Europe and the 
United States of America (USA), and the sixth leading cause of cancer related-deaths, 
accounting for 14% (903,500) of total new diagnosed cancer cases and 6% (258,400) of whole 
cancer deaths in males in 2008 [1]. Because the increased use of screening techniques testing 
serum concentrations of prostate-specific antigen (PSA) has meant that PCa is more commonly 
diagnosed and can be detected at an earlier stage, the incidence rates recorded primarily in the 
developed countries, such as Oceania, Europe and North America, were hight. In contrast, 
males of African individuals in the Caribbean region have the highest PCa mortality rates in 
the world, which is thought to reflect partly difference in genetic susceptibility [2, 3]. 
Death rates for PCa have been decreasing in many developed countries, including Australia, 
Canada, USA, the United Kingdom, Italy and Norway in part due to the improved 
treatment with curative intent [4-6]. Recently, one European-based trial on the efficacy of 
PSA testing could reduce the rate of death from PCa by 20% [7]. In contrast to the trends of 
western countries, incidence and mortality rates are rising in several Asian and 
central/eastern-European countries, such as Japan, China and Poland, suggesting an 
increasingly westernized lifestyle in these regions [4, 5]. The underlying etiology of PCa 
remains poorly understood, with both genetic predisposition and environmental factors 
(diet, lifestyle, older age, race, family history and hormone) likely to play an important role 
[8-10]. Despite this strong evidence for a genetic component in PCa, little progress has been 
made to identify a major gene or genes [11]. 
Tumor necrosis factor-related apoptosis inducing ligand (TRAIL) is a novel member of the 
TNF super-family and was first identified by Wiley in 1995 [12]. TRAIL is mapped to the 
long arm of chromosome 3q26 in humans and is composed of five exons. It encodes 1.77 kb 
mRNA. Similar to FasL, TRAIL is also a type II membrane protein which induces apoptosis 
in a wide variety of cancer cells and spares normal cells [12]. TRAIL-induced apoptosis is a 
multi-step process: it binds to death receptor 4 (DR4) and DR5 cell surface receptors leading 
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to the formation of the death inducing signaling complex (DISC) that recruits caspase-8 via 
the adaptor protein Fas-associated with death domain protein (FADD). The formation of 
DISC and recruitment of caspase-8 leads to proteolytic activation of caspase-3 and caspase-7 
leading to DNA fragmentation and apoptosis [13-15] (Fig. 1). 
 
 
Fig. 1. TRAIL pathway for cancer therapy. DR4 and DR5 activation by PARAs (either trimeric 
rhApo2L/TRAIL or agonistic DR4 or DR5-specific antibodies) or Apo2L/TRAIL expressed by 
innate immune cells. FADD is recruited to DR4 or DR5 located within lipid raft containing 
regions of the membrane, which promotes receptor clustering and autocatalytic processing of 
the apoptosis initiating proteases caspase-8 or caspase-10 to form the active DISC. Caspase-8 
can be polyubiquitylated at the DISC by a cullin-3/Rbx1-based E3 ubiquitin ligase, which 
facilitates caspase-8 activation. This process is negatively regulated by the de-ubiquitinating 
enzyme, A20. The signaling adaptor p62 can bind to ubiquitilated caspase-8 and translocate it 
to ubiquitin-rich foci, which may also enhance its activity. In many cancer cells, proapoptotic 
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signaling involves the mitochondrial pathway via caspase-8-mediated cleavage of Bid to t-Bid. 
Proapoptotic signaling through the intrinsic pathway is further regulated by pro apoptotic and 
anti apoptotic members of the Bcl-2 family. Receptor tyrosine kinase (RTK) signaling and 
chemotherapy or radiotherapy can further modulate the intrinsic proapoptotic pathway 
through targeting Bcl-2 family members. Under certain circumstances, DR4 or DR5 signaling 
can promote alternative signaling pathways such as JNK, MAPK or NFkB, which may require 
recruitment of RIP1 and TRAF2 or TRAFs5 to form secondary signaling complexes. Depicted 
in blue are inhibitors that may enhance proapoptotic signaling by PARAs by targeting 
mechanisms of resistance in tumor cells. (This picture was cited from Yang et al. [50] Current 
Opinion in Cell Biology. 2010) 
Several single nucleotide polymorphisms (SNPs) present along the TRAIL gene located in 
the 3q26 region have been found in both healthy and disease individuals, including four 
SNPs in the 5’ regulatory region [16], two SNPs within exons, and five SNPs in the 3’ 
untranslated regions[17-18]. TRAIL gene polymorphisms were also identified in patients 
with multiple sclerosis [19, 20] and fatty liver disease [21]. 
Recently, a SNP of -716A>G polymorphism (rs12488654) in the promoter region of TRAIL 
gene has been found to be associated with breast cancer with functional implications both in 
vitro and vivo studies [22]. To date, there have been no data about the association between 
this polymorphism and PCa, so we first explored the role of the TRAIL A>G polymorphism 
in PCa patients in southern Chinese Han descent. Moreover, we detected the serum levels of 
TRAIL expression with different genotypes in cases to characterize the functional 
consequences of TRAIL -716 A>G polymorphism. 
2. Materials and methods 
2.1 Study population 
One hundred and eighty-seven PCa patients were newly diagnosed between November 
2009 and May 2010 in the First Affiliated Hospital of Nanjing Medical University (Jiangsu 
Province Hospital) in Nanjing, China. All PCa cases were between 51 and 94 years of age 
and were diagnosed with the disease within the last one year; all controls were between 47 
and 96 years of age. All cases were diagnosed with PCa through needle biopsy 
(ultrasoundguided transrectal needle biopsy of prostate, 13-fold biopsy) or operation 
(radical prostatectomy and transurethral resection of the prostate). All the patients were 
southern Chinese Han descent. The control group (n = 237) was age-matched and the 
subjects were healthy checkup examinees without cancer history and were collected in the 
same period. Controls were excluded if they ever had abnormal appearance of pathology, 
abnormal prostate-specific antigen test (i.e., ≥ 4 ng/ml), abnormal digital rectal examination, 
other previous cancer diagnosis, symptom of any prostate disease or abnormal appearance 
of other auxiliary examination including computed tomography urography (CTU), magnetic 
resonance urography (MRU), positron emission tomographic (PET), transrectal 
ultrasonography and so on. 
After informed consent was obtained, 2 ml peripheral blood sample was collected and each 
subject was asked to finish a questionnaire including age, weight, height, race, tobacco use, 
alcohol use, family history of cancer and so on. In our present research, smoking more than 
five cigarettes per day for more than 5 years was defined as smoking; drinking habit was 
defined as drinking at least three times per week and lasting more than 10 years; family 
history of cancer was defined as cancer in first-degree relatives (parents, siblings, or 
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children); disease stage was determined by pathologic findings, pelvic computed 
tomography, magnetic resonance image and radio-nucleotide bone scans, the tumor stage 
was determined using tumor-node-metastasis (TNM) classification and graded according to 
WHO guidelines; pathologic grade was recorded as the Gleason score. 
2.2 Genotyping 
Polymorphisms were analyzed by polymorphism chain reaction and ligase detection 
reaction (PCR-LDR). Each PCR reaction was done in a total volume of 15 ul, which contains 
1 ul genomic DNA, 2.5 pmol of each promer, 10× buffer 1.5 ul, MgCl2 1.5 ul, 0.3 ul of dNTP 
(MBI, Inc.), 0.25 ul of Taq DNA Polymerase (MBI, Inc.) and ddH2O 9.95 ul. PCR was 
subjected to 35 thermal cycles at 94°C 15 sec, 56°C for 15 sec, and 72°C for 60 sec conducted 
on the ABI 9600 (ABI, Inc.). Primers were 5’-TGACGACTTCTTCCTCTTTGC-3’ (sense) 5’- 
GATAGTGACAGCGAGACATTG-3’ (antisense). The probes for LDR were: 5’-P-
GTAGGAAGTAGTTGACACACTCAGATTT-FAM-3’ with common phosphorylated 5’-end 
and 6-carboxy X-uorescein (FAM) labeled 3’-end, the A-specific probe 5’ 
TTTTCATGCCTGTGTGTTAGGCTGCACAA-3’, the G-specific probe 5’-
tttttTTCATGCCTGTGTGTTAGGCTGCACAG-3’. For each PCR product, the ligation 
reaction was performed in a final volume of 10 ul, which contains 3 ul PCR product, 10×Taq 
DNA ligase buffer 1 ul, 5 U of Taq DNA ligase (NEB, Inc.,), 0.1 pmol of each probe, and 
ddH2O 5.575 ul. The LDR parameters were as follows: 25 thermal cycles at 94 °C for 30 sec 
and 60°C for 30 min. The LDR reaction products were analyzed on ABI 3730 DNA 
Sequencer (ABI, Inc.,). To confirm the accuracy of PCR-LDR genotyping method, direct 
DNA sequencing of randomly selected PCR products was performed. The proportion of the 
sequencing samples were about 5%, the results of the PCR-LDR genotyping showed 100% 
concordance to direct DNA sequencing of the randomly selected PCR products. 
2.3 Enzyme-linked immunosorbent assay (ELISA) 
Blood was collected in standard cubes without anticoagulant and was immediately 
centrifuged for 20 min, at 3,000 rpm. Serums were stored at -808°C until serum TRAIL levels 
were measured by ELISA kit (R&D Systems, Inc.). The optical density was determined by 
measuring the absorbance at 450 nm. The absorbance was correlated against a standard 
curve. 
2.4 Statistical analysis 
Hardy–Weinberg equilibrium (HWE) was tested among controls using the Pearson chi-
square test. Differences in the distributions of demographic characteristics, selected variables 
and frequencies of genotypes of TRAIL -716 A>G polymorphism between the cases and 
controls were evaluated by using the student’s t-test (for continuous variables) or chi-square 
(χ2) test (for categorical variables). The odds ratios (OR) and 95% confidence internals (CI) 
were calculated by logistic regression analysis to quantify the association between TRAIL -716 
A>G polymorphism and risk of PCa with the adjustment for potential covariates (age, BMI, 
cigarette smoking, alcohol drinking and family history of cancers). The correlation between the 
serum TRAIL levels and genotypes of TRAIL -716 A>G polymorphism were evaluated by one-
way ANOVA. A P-value < 0.05 was considered statistically significant and all statistical tests 
were two sided. All statistical analyses were performed with Statistics Analysis System 
software (Version 9.1.3; SAS Institute, Inc., Cary, NC). 
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3. Results 
3.1 Characteristics of the study population 
One hundred and eighty-seven patients and 237 cancer-free controls were enrolled in our 
study. The distribution of relevant demographic and clinical characteristics is presented in 
Table 1. Baseline characteristics were similar between cases and controls, except that the 
frequency of relatives with cancer from the case group was higher, compared to non-
relatives (27.27% vs. 15.61%, P = 0.003); there were more subjects who had larger body mass 
index (>23 kg/m2) among the cases than among the controls (60.43% vs. 50.21%, P = 0.036), 
the frequency of ever alcohol drinking in cases was higher than in controls (34.22% vs. 
20.68%, P = 0.002) and the mean ± SD PSA levels of PCa patients and control subjects were 
80.45 ± 262.25 and 2.14 ± 1.42 ng/ml, respectively (P < 0.001). 
 
Characteristics 
Csaes (n=187) Controls (n=237) 
P-Value 
n % n % 
Age (year)    0.687 
≤70 55 29.41 74 31.22  
＞70 132 70.59 163 68.78  
BMI (kg/m2)     0.036 
≤23 74 39.57 118 49.79  
＞23 113 60.43 119 50.21  
Cigarette smoking     0.839 
  Never 81 43.32 105 44.30  
Ever 106 56.68 132 55.70  
Alcohol drinking     0.002 
  Never 123 65.78 188 79.32  
Ever 64 34.22 49 20.68  
Family history of cancers     0.003 
No 136 72.73 200 84.39  
Yes 51 27.27 37 15.61  
PSA(ng/ml)      
Mean ± SD 80.45  ±262.25 2.14 ±1.42 ＜0.001 
Clinical stage      
Localized 86 46.00    
Advanced 101 54.00    
Gleason score      
＜7 50 26.74    
= 7 70 37.43    
＞7 67 35.82    
BMI: body mass index 
Table 1. Demographic characteristic of PCa cases and controls 
3.2 Genotype distributions of TRAIL -716 A>G polymorphism and risk of PCa 
The distribution of TRAIL -716 A>G in the control group was 21.10% for AA homozygote, 
51.48% for AG heterozygote, 27.42% for GG homozygote, and was in Hardy–Weinberg 
equilibrium (χ2 = 0.268, P = 0.604). As shown in Table 2, the TRAIL -716 A>G polymorphism 
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was not associated with total PCa. After adjusting for potential covariates (age, BMI, 
cigarette smoking, alcohol drinking, family history of cancers), compared with AA 
homozygote, subjects carrying GG homozygote did not have any association between cases 
and controls (OR = 0.94, 95%CI = 0.69-1.27, P = 0.397). In addition, no association was also 
found between subjects carrying AG/GG genotypes and AA homozygote (OR = 0.87, 95%CI 
= 0.54-1.41, P = 0.577). 
 
Genotype PCa, No. (%) Controlsa, No. (%) P-valueb Adjusted OR(95%CI)c 
Total 187 237   
AA 44(23.53) 50(21.10)  1.00(reference) 
AG 98(52.41) 122(51.48) 0.712 0.89(0.54-1.47) 
GG 45(24.06) 65(27.42) 0.397 0.94(0.69-1.27) 
AA 44(23.53) 50(21.10)  1.00(reference) 
AG+GG 143(76.47) 187(78.90) 0.577 0.87(0.54-1.41) 
aThe genotype frequencies among the control subjects were in agreement with the Hardy-Weinberg 
equilibrium (χ2 = 0.268, P = 0.604). 
bTwo-sided χ2 test for the distributions of genotypes frequencies between the cases and controls. 
cOdd ratios (ORs) were obtained from a logistic regression model with adjusting for age, BMI, cigarette 
smoking, alcohol drinking, family history of cancers; 95%CI, 95% confidence interval. 
Table 2. Genotypes in patients with PCa and controls 
3.3 Stratified analysis 
The association between genotypes and PCa risk stratified by disease stage (Localized: T1-
2N0M0; Advanced: T3-4NXMX or TXN1MX or TXNXM1), pathologic grade (Gleason score < 7, = 
7 and >7) and serum PSA level (≤ 20 and >20) is shown in Table 3. These associations were 
in the same direction for advanced, higher grade disease and PSA level but were not 
statistically significant.  
 
Variables 
TRAIL-716A/G 
P-valuea Adjusted OR (95% CI)b 
AA,No.(%) AG/GG,No.(%) 
Control 50(21.10) 187(78.90)  1.00(reference) 
Clinical stagec     
Localized 15(17.65) 70(82.35) 0.644 1.17(0.60-2.27) 
Advanced 29(28.43) 73(71.57) 0.158 0.67(0.38-1.17) 
Gleason score     
<7 6(12.00) 44(88.00) 0.117 2.14(0.83-5.53) 
= 7 19(27.14) 51(72.86) 0.226 0.68(0.36-1.27) 
>7 19(28.36) 48(71.64) 0.117 0.59(0.31-1.14) 
PSA     
≤ 20 16(17.58) 75(82.42) 0.626 1.17(0.62-2.23) 
>20 28(28.87) 69(71.13) 0.121 0.64(0.36-1.13) 
aTwo-sided χ2 test for the distributions of genotypes frequencies between the cases and controls. 
bOdd ratios (ORs) were obtained from a logistic regression model with adjusting for age, BMI, cigarette 
smoking, alcohol drinking, family history of cancers; 95%CI, 95% confidence interval. 
cLocalized: T1-2N0M0; Advanced: T3-4NXMX or TXN1MX or TXNXM1 [according to the international 
tumor-node-metastasis (TNM) staging system for PCa]. 
Table 3. TRAIL-716A/G and clinico-pathological characteristics in patients with PCa 
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In addition, as show in Table 4, the association between TRAIL -716 A>G polymorphism 
and PCa did not vary by cigarette smoking and alcohol drinking. However, the association 
appeared stronger in subgroups of BMI >23kg/m2 (OR = 0.58, 95%CI = 0.31-0.89), age ≤70 
years (OR = 0.32, 95%CI = 0.12-0.87) and no family history of cancers (OR = 0.86, 95%CI = 
0.51-0.96). 
 
Variables 
N 
(case/control)
Genotypes(case/control) 
P-valuea 
Adjusted 
OR(95%CI)
b 
AA genotype AG/GG genotype
n % n % 
Total 
187/237 44/50 
  23.53/ 
21.10 
  143 
/187 
  76.47/ 
78.90 
0.577 
0.87 
(0.54-1.41) 
Age(years)       
 ≤ 70 55/74 13/9 
  23.64/ 
12.16 
42/65
  76.36/ 
87.84 
0.026 
0.32 
(0.12-0.87) 
>70 
132/163 31/41 
  23.48/ 
25.15 
  101/ 
122 
  76.52/ 
74.85 
0.575 
1.17 
(0.67-2.04) 
BMI (kg/m2)       
 ≤ 23 74/118 12/27 
  16.22/ 
22.88 
62/91
  83.78/ 
77.12 
0.165 
1.78 
(0.79-3.99) 
>23 
113/119 32/23 
  28.32/ 
19.33 
81/96
  71.68/ 
80.67 
0.042 
0.58 
(0.31-0.89) 
Cigarette smoking       
Never 
81/105 20/26 
  24.69/ 
24.76 
61/79
  75.31/ 
75.24 
0.967 
0.99 
(0.49-1.97) 
Ever 
106/132 24/24 
  22.64/ 
18.18 
 82/ 
108 
  77.36/ 
81.82 
0.535 
0.81 
(0.41-1.58) 
Alcohol drinking       
Never 
123/188 29/39 
  23.58/ 
20.74 
 94/ 
149 
  76.42/ 
79.26 
0.513 
0.83 
(0.48-1.45) 
Ever 
64/49 15/11 
  23.44/ 
22.45 
49/38
  76.56/ 
77.55 
0.944 
0.97 
(0.38-2.45) 
Family history of cancers       
No 
136/200 34/44 
  25.00/ 
22.00 
  102/ 
156 
  75.00/ 
78.00 
0.034 
0.86 
(0.51-0.96) 
Yes 
51/37 10/6 
  19.61/ 
16.22 
41/31
  80.39/ 
83.78 
0.972 
1.02 
(0.31-3.32) 
aTwo-sided χ2 test for the distributions of genotypes frequencies between the cases and controls. 
bOdd ratios (ORs) were obtained from a logistic regression model with adjusting for age, BMI, cigarette 
smoking, alcohol drinking, family history of cancers; 95%CI, 95% confidence interval. BMI: body mass 
index. 
Table 4. Association and stratification between TRAIL-716A/G and PCa risk. 
3.4 Association of TRAIL -716 A>G polymorphism with expression levels of TRAIL 
We collected 83 tumor serum samples obtained from in present study with different 
genotypes of the TRAIL -716 A>G polymorphism, and the distribution of the AA, AG, and 
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GG genotypes was 27 (32.53%), 44 (53.01%) and 12 (14.46%), respectively. Moreover, serum 
TRAIL levels in PCa patients with AG/GG genotypes were significantly higher than those 
with AA genotypes (901.18 ± 189.58 µg/L vs. 819.13 ± 111.00 µg/L, P = 0.041; Fig. 2) 
 
 
Fig. 2. Analysis of serum TRAIL levels in three groups of PCa cases with mean values 
(horizontal lines, mean values). * P = 0.041 compared with the AG/GG and AA genotypes. 
4. Discussion 
Recently, Kuribayashi et al. [23] indicated a direct regulation of TRAIL gene by p53 protein. 
Moreover, early growth response protein (EGR) [24], interferon regulatory factor 1 (IRF1) 
[25], NF-kB [26], SP1 [27] and PU1 [28] have been implicated in the regulation of TRAIL. 
TRAIL is present in various tissues, particular in the prostate, spleen and lung. 
TRAIL binds to two different types of receptors: death receptors and decoy receptors. 
TRAIL can also bind to osteoprotegerin (OPG) (a soluble inhibitor of receptor activator of 
NF-kB ligand) at low affinity. To date, four human receptors specific for TRAIL have been 
recognized: the death receptors TRAIL-R1 (also know as DR4), TRAIL-R2 (also known as 
DR5), the putative decoy receptors TRAIL-R3 (DcR1) and TRAIL-R4 (DcR2). TRAIL-R1 
(DR4) is expressed at very low levels in most human tissues including the spleen, thymus, 
liver, peripheral blood leukocytes, activated T cells, small intestine and some tumor cell 
lines. TRAIL-R2 (DR5) is ubiquitiously distributed both in normal and tumor cell lines but is 
more abundant in spleen, peripheral blood leukocytes, activated lymphocytes and 
hepatocyes [29-31]. 
TRAIL has attained the centre stage in anti-tumor drug discovery because of its efficacy in 
killing tumor cells without lethal toxicity in pre-clinical models apart from the inherent 
property to activate both the extrinsic and intrinsic apoptotic pathways [32-34]. 
Single nucleotide polymorphisms (SNPs) are the most abundant form of genetic variation in 
the human genome. By convention, a point mutation is referred to as a SNP when the 
frequency of the minor (rarer) allele exceeds 1% in at least one population. For example, a 
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SNP in a regulatory region may have an influence on gene transcription, a SNP located in a 
RNA splice site may affect RNA splicing, a SNP in the 3’-untranslated region of a gene may 
have an effect on mRNA stability, and a SNP in the coding region may result in an amino 
acid substitution in the encoded protein. It is thought that SNPs contribute to 
interindividual variability in susceptibility to common diseases such as cancer [35, 36]. 
So far, some published meta-analyses have confirmed that a number of SNPs are 
associated with increased or decreased PCa risk in different races, such as A49T in 
steroid-5-alpha-reductase, alpha polypeptide 2 (SRD5A2) gene [37], Gly388Arg in 
fibroblast growth factor receptor 4 (FGFR4) gene [38], -160C/A in E-cadherin (CDH1) 
gene [39], Val16Ala in manganese superoxide dismutase (MnSOD) gene [40], C677T in 
5,10-methylenetetrahydrofolate reductase (MTHFR) gene [41]. 
Several studies have investigated the possible role of anti-tumor gene polymorphisms and 
the prevalence of PCa. This impairment of host factors might result in susceptibility or 
resistance to tumor progression. The transcription factor Sp3 (stimulatory protein 3) exhibits 
a similar DNA binding affinity for Sp1 consensus sequence [42-44] and represses the Sp1-
mediated trans-activation of promoters with two or more Sp1 sites [45-47]. TRAIL has two 
Sp1 consensus sequences in the basal promoter [48, 49]. AA genotype at -716 in TRAIL 
promoter with additional Sp1 consensus sequence can decrease TRAIL expression due to 
the repression caused by binding of Sp3, whereas, GG genotype background at the same 
position can increase TRAIL expression because of the lower probability of Sp3 driven 
repression. To date, only one study [22] showed the association between TRAIL -716 A>G 
polymorphism and cancer risk: individuals with -716 GG genotype were at a greater risk 
of developing breast cancer, in addition, G allele resulted in a higher expression than the 
A allele to regulate the expression of TRAIL in four different cancer cell lines (HeLa, MCF-
7, HepG2, HT1080). 
To the best of our knowledge this is the first study investigating the genetic association of 
polymorphism of the -716 site in TRAIL gene with PCa and the expression of TRAIL with 
different genotypes in serum of cases in southern Chinese Han descent. No statistically 
significant association was observed between TRAIL -716 A>G polymorphism and PCa. 
Moreover, when stratifying the case group by clinical characteristics, the present study 
also did not find any association among PSA, Gleason and clinical stage. There must be 
some factors that would contribute to this discrepancy. First, TRAIL -716 A>G 
polymorphism might play a different role in different cancers. Second, multiple genes and 
environmental factors may lead to cancer formation. Third, race may be related to cancer. 
Either through common risk factors or other genes in linkage disequilibrium with TRAIL 
suggests that a possible role of ethnic differences is in genetic backgrounds and the 
environment they lived in. 
Furthermore, we found that the decreased risk associated with the AG/GG genotypes was 
more pronounced in: subjects with age ≤70 years (OR = 0.32, 95%CI = 0.12-0.87) and no 
family history of cancers (OR = 0.86, 95%CI = 0.51-0.96). It confirmed the concept that 
younger age and no family history of cancers might be protective factors for PCa. In 
addition, we found that the OR for AG/GG genotypes was 0.58(95%CI = 0.31-0.89) among 
subjects with BMI >23kg/m2. This finding may reflect that PCa formation may be subject to 
a variety of environmental and genetic factors. In these subgroups, other high level of 
genetic susceptibilities or other unknown risk factors may influence our results. 
Except for above associated results, we detected the expression of TRAIL in the serums of 
the cases. We found that the protective genotypes AG/GG were associated with higher 
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serum TRAIL expression when compared with the AA genotype. Previous one study [22] 
have reported that the G allele resulted in a higher expression than the A allele. Our work 
confirmed the findings of this study. Furthermore, since TRAIL can be measured in the 
blood and the serum level has been found significantly different in different genotypes in 
PCa cases, this may be a novel tumor marker and provide a future screening target. We 
need further investigations on the molecular mechanisms of how genetic variants might 
affect the TRAIL expression. 
This study has several potential limitations. First of all, it is well known that sporadic and 
familial PCa have frequently quite different epidemiological and molecular peculiarities, 
clinical evolution and prognosis, so it is better to analysis these two kinds of PCa, 
respectively, however, we got together as a whole case group. Second, the numbers of 
cases/controls in our studies were not sufficiently large for a comprehensive analysis. Third, 
the control group in our study contained not only the healthy old matched man but also the 
benign prostatic hyperplasia (BPH), which was not the strict ‘control’. 
5. Conclusions 
Our study suggested that a functional polymorphism -716 A>G in the TRAIL gene may play 
a role in the development of PCa in southern Chinese Han descent, and the protective 
genotypes AG/GG of -716 A>G were associated with increased TRAIL expression in serum, 
which makes it a potential role in early detection for PCa. Moreover, further investigations 
with larger sample size are needed to confirm this relationship and to elucidate the 
mechanism responsible for this association. 
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